PathHunter® Aflibercept Bioassay Kit

The PathHunter® Aflibercept Bioassay kit provides an easy-to-use cell based assay to determine Aflibercept potency and detect neutralizing antibodies. This bioassay assesses VEGFA-induced dimerization of VEGFR2 receptors.

View bioassay qualification data.

Catalog #: 93-0996Y1-00005

$1,989.00$9,979.00


Inquire
Biological Information
Background Information:
The PathHunter® Aflibercept Bioassay kit provides an easy-to-use cell based assay to determine Aflibercept potency and detect neutralizing antibodies. This bioassay assesses VEGFA-induced dimerization of VEGFR2 receptors. This product uses EFC technology. The included cells overexpress VEGFR2 target protein fused to PK alongside VEGFR2 target protein fused to EA. Upon ligand-induced dimerization of VEGFR2, detectable EFC signal is produced. This bioassay has been optimized and qualified with the marketed biologic drug, Eylea® which is not provided in the bioassay kit. Eyelea® is a registered trademark of Regeneron Pharmaceutical, Inc. Bioassay kits are a convenient, ready-to-use format which contains all materials needed to run the assay, including single-use vials of cryopreserved cells, cell plating media, control agonist, detection reagent, and assay plates
Target Class:
Kinase
Family:
Receptor Typosine Kinase (RTK): Growth Factor Receptor
Accession Number:
NM_002253.2
Target Name:
KDR/KDR
Target Aliases:
Kinase Insert Domain Receptor, FLK1, CD309, VEGFR, VEGFR2
Target Species:
Human
Cell Background:
HEK293
Usage
Product Type:
Bioassay Kits
Application:
Potency; Commercial Release & Stability
Kit Components:
Storage Conditions:
Store in vapor phase of liquid nitrogen.
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Assay Information
Assay Type:
Functional
Assay Measures:
Dimerization
Detection Method:
Chemiluminescence
Bioassay Data
Qualified With:
Eylea®
Trademark Statement:
Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Additional Information
Brand:
PathHunter®

User Manuals & Protocols

70-326 PathHunter Aflibercept Bioassay Kit User Manual REV5

View Document

Datasheets

93-0996Y1x Datasheet

View Document